Abstract

1148P Avelumab as second-line or later (2L+) treatment (tx) in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Real-world tx patterns in France

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call